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Background: Torsades de pointes (TdP) is a life-threatening ventricular tachycardia
occurring in long QT-syndrome patients. It usually develops when multiple QT-prolonging
factors are concomitantly present, more frequently drugs and electrolyte imbalances.
Since proton–pump inhibitors (PPIs)-associated hypomagnesemia is an increasingly
recognized adverse event, PPIs were recently included in the list of drugs with conditional
risk of TdP, despite only few cases of TdP in PPI users have been reported so far.
Objectives: Aim of the present study is to evaluate whether PPI-induced
hypomagnesemia actually has a significant clinical impact on the risk of TdP in the general
population.
Methods: Forty-eight unselected patients who experienced TdP were consecutively
enrolled (2008-2017). Shortly after the first TdP episode, in those patients who did not
receive magnesium sulfate and/or potassium or calcium replacement therapy, serum
electrolytes were measured and their relationship with PPI usage analyzed.
Results: Many patients (28/48, 58%) were under current PPI treatment when TdP
occurred. Among TdP patients in whom serum electrolyte determinations were obtained
before replacement therapy (27/48), those taking PPIs had significantly lower serum
magnesium levels than those who did not. Hypomagnesemia occurred in ∼40% of
patients receiving PPIs (6/14), in all cases after an extended treatment (>2 weeks). In
patients taking PPIs the mean QT-prolonging risk factor number was significantly higher
than in those who did not, a difference which was mainly driven by lower magnesium
levels.
Conclusions: In unselected TdP patients, PPI-induced hypomagnesemia was common
and significantly contributed to their cumulative arrhythmic risk. By providing clinical
support to current recommendations, our data confirm that more awareness is needed
when a PPI is prescribed, specifically as regards the risk of life-threatening arrhythmias.
Keywords: proton-pump inhibitors, Torsades de pointes, serum magnesium levels, long-QT syndrome, sudden
cardiac death
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INTRODUCTION
Torsades de pointes (TdP) is a life-threatening polymorphic
ventricular tachycardia that can degenerate into ventricular
fibrillation (VF) and cause sudden cardiac death (SCD) (Drew
et al., 2010). It is characterized by a pattern of twisting points and
occurs in patients with long QT syndrome (LQTS), both acquired
and congenital. Indeed, in congenital-LQTS the more the heart
rate-corrected QT interval (QTc) prolongs, the greater the TdP
risk exponentially increases (i.e., 5–7% risk increase each 10ms
prolongation in QTc) until being significant for QTc>500ms;
such a value associated with a 2–3-fold higher risk for TdP (Drew
et al., 2010).
Since a marked QTc prolongation is usually required for
TdP development, in most cases the simultaneous presence
of multiple QTc-prolonging factors synergistically operating
in impairing ion channels responsible for the ventricular
repolarization process is necessary. Congenital factors are
included, mainly resulting from mutations affecting genes
encoding for potassium or sodium channels, as well as acquired
risk factors (Viskin, 1999; El-Sherif and Turitto, 2003; Drew et al.,
2010; Itoh et al., 2016). Among the latter factors, electrolyte
imbalances (i.e., hypokaliemia, hypocalcemia, hypomagnesemia)
and QT-prolonging drugs blocking the hERG potassium channel
are those most frequently implicated in TdP development.
Other established causes of acquired LQTS and TdP include
structural heart diseases, bradyarrhythmias, endocrine disorders,
liver diseases, nervous system injuries, HIV infection, starvation,
hypothermia and toxins (El-Sherif and Turitto, 2003; Drew
et al., 2010). In addition, autoimmunity (Lazzerini et al., 2017d)
(particularly anti-Ro/SSA antibodies) (Yue et al., 2015; Lazzerini
et al., 2016) and systemic inflammation (Lazzerini et al., 2015,
2017a,b) in the recent years are being increasingly recognized
as novel acquired QT-prolonging risk factors significantly
impacting TdP risk in the general population.
Proton–pump inhibitors (PPIs) are the most effective
therapeutic agents for acid related disorders (ARD), including
peptic ulcer disease and gastroesophageal reflux disease (Strand
et al., 2017). Moreover, such drugs are also used for the
prevention of non-steroidal anti-inflammatory drug-induced
gastric injury and as a part of Helicobacter pylori eradication
regimens (Strand et al., 2017). As a result, PPIs currently
represent the fifth best-selling drug in the market with millions of
chronic users worldwide (Patterson Burdsall et al., 2013). During
the last years, concern has been raised because of PPIs long-
term overutilization. In fact, in the clinical practice PPIs are often
prescribed in patients without a specific ARD, and such a habit
is leading to significant cost expenditure and possible adverse
events (Moayyedi and Leontiadis, 2012).
Hypomagnesemia is a potentially serious side effect of PPIs,
that could account for∼1% of all adverse events reported by drug
users (Famularo et al., 2013; Luk et al., 2013). Although several
data suggest an interference on intestinal magnesium absorption,
the exact underlying mechanism is poorly understood (Famularo
et al., 2013). In 2011 the US FDA warned that long-term
use of PPI has the potential to reduce circulating magnesium
levels, particularly in patients concomitantly receiving other
drugs capable to cause magnesium depletion such as diuretics
(2011)1. Accordingly, in 2016 the Arizona Center for Education
and research on Therapeutics (AZCERT) included the PPIs
omeprazole, esomeprazole, lansoprazole and pantoprazole in the
list of drugs with conditional risk of TdP and to be avoided in
patients with congenital LQTS (AZCERT, 2016), despite only
few cases of QTc prolongation and TdP have been reported in
patients with severe PPI-induced hypomagnesemia and/or taking
a PPI concomitantly with drugs known to directly prolong QTc
(Asajima et al., 2012; Bibawy et al., 2013; Hansen and Bruserud,
2016). As a result, it is now recommended that in patients taking a
PPI for an extended period of time (>2 weeks) serummagnesium
levels be monitored periodically, particularly if extended PPI
therapy is used in association with drugs carrying a known
risk of TdP (Asajima et al., 2012; 2016). Notably, a very recent
longitudinal observational study performed in a large primary
cohort of new users of acid suppression therapy followed for a
median of 5.7 years, found a significant association between PPI
use and risk of all-cause mortality. The risk was increased among
those with no documented medical indications for PPI use and
prolonged duration of use (Xie et al., 2017).
Regardless of official recommendations, available real-life
information on this subject is relatively poor so far. The present
study is specifically aimed at evaluating whether PPI-induced
hypomagnesemia has a significant clinical impact on the risk of
TdP in the general population. Thus, the actual usage of PPIs and
its relationship with serum magnesium levels were analyzed in a
cohort of TdP patients, prospectively and consecutively enrolled
independent of ongoing therapies and concomitant diseases.
PATIENTS AND METHODS
Study Populations
Local Ethical Committee approved the study, and patients gave
their oral and written informed consent in accordance with the
Principles of the Declaration of Helsinki.
We prospectively enrolled (from January 2008 to May 2017)
48 consecutive hospitalized patients who presented with TdP,
independent of ongoing therapies and concomitant diseases.
Since the only inclusion criteria was the occurrence of TdP, all
patients who came to our attention in that period of time were
enrolled. No patients were excluded. Demographic, clinical and
laboratory characteristics of study patients, as well as ongoing
treatment with QTc-prolonging medications are provided in
Table 1. In these patients, PPI usage was assessed, and a cut-
off time of 2 weeks was used to define treatment duration as
extended (>2 weeks) or not, according to current AZCERT
recommendations to minimize the risk of TdP in patients treated
with PPI (AZCERT, 2016).
ECG Recordings
Diagnosis of TdP was based on the presence of at least one
episode of polymorphic ventricular arrhythmia at a rate ranging
1FDA Drug Safety Communication: Low magnesium levels can be associated with
long-term use of proton pump inhibitor drugs (PPIs). Available at www.fda.gov/
Drugs/DrugSafety/ucm245011.htm Accessed May 26 (2017).
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TABLE 1 | Demographic, clinical and laboratory characteristics of patients with
Torsades de pointes.
Patients, n 48
Age, median years (interquartile range) 81(73–85)
Females, n 31/48(65%)
Mean QTc, ms(range) 596.0 ± 80.7(490–910)
Electrolyte imbalances, n 37/47(79%)
Hypokaliemia 28/45(62%)
Hypocalcemia 22/37(59%)
Hypomagnesemia 7/27(26%)
Concomitant diseases*, n 45/48(94%)
Cardiac diseases 40/48(83%)
Left ventricular hypertrophy 19/48(40%)
Dilated cardiomyopathy/heart failure 13/48(27%)
II-III degree atrioventricular block 10/48(21%)
Acute coronary syndrome 9/48(19%)
Chronic coronary artery disease 7/48(15%)
Sinus bradycardia 6/48(13%)
Extra-cardiac diseases 20/48(42%)
Diabetes mellitus type II 13/48(27%)
Chronic kidney disease 8/48(17%)
Hypothyroidism 2/48(4%)
Subarachnoid hemorrhage 1/48(2%)
Cirrhosis 1/48(2%)
Anorexia nervosa 1/48(2%)
HIV infection 1/48(2%)
QTc prolonging-medications, n 34/48(71%)
Amiodarone 14/48(29%)
Citalopram 5/48(10%)
Sertraline 4/48(8%)
Fluconazole 3/48(6%)
Trazodone 3/48(6%)
Levofloxacin 2/48(4%)
Clarithromycin 2/48(4%)
Promazine 2/48(4%)
Quetiapine 2/48(4%)
Mean medication number per patient 1.1 ± 1.0
Anti-Ro/SSA positivity, n 18/32(56%)
Systemic inflammation, n† 38/48(79%)
C-reactive protein, mg/dl(range) 2.66(0.1–29.65)
Definite inflammatory diseases 22/48(46%)
Acute infections 15/48(31%)
Immuno-mediated diseases 5/48(10%)
Others 2/48(4%)
Mean QTc-prolonging risk factor number per patient§ 5.3 ± 1.5
Except where indicated otherwise, data are expressed as mean ± standard deviation or
median (range).
Appropriate serum potassium, calcium or magnesium measurements available in 45, 37,
and 27 out of 48 patients, respectively; anti-Ro/SSA antibodies tested in 32 out of 48
patients.
*Diseases recognized to be a risk factor for QTc prolongation (Viskin, 1999; El-Sherif and
Turitto, 2003; Drew et al., 2010).
†
Increased C-reactive protein level (>0.5 mg/dl) with or without a definite inflammatory
disease. § Including electrolyte imbalances, diseases, QTc-prolonging medications, anti-
Ro/SSA positivity, and systemic inflammation (Viskin, 1999; El-Sherif and Turitto, 2003;
Drew et al., 2010; Yue et al., 2015; Lazzerini et al., 2016, 2017b).
from 160 to 240 beats/min, associated with QTc prolongation
(Drew et al., 2010; Figure 1). The QT interval was manually
measured on a standard 12-lead ECG, from the onset of the
Q wave or the onset of the QRS complex to the end of
the T wave, defined as the return to the T-P baseline. When
present, prominent U waves (>1mm) merging into T waves
were included in QT measurement (Gupta et al., 2007). QTc,
determined as the longest hand-measured QTc in any lead
(Rautaharju et al., 2009) was corrected for heart rate by the Bazett
formula (dividing the QT by the square root of the preceding R-R
interval of each beat: QT/
√
RR) to yield the QTc value. QTc was
measured from 3 non-consecutive beats (mean value) by a single
investigator.
Laboratory Analysis
Shortly after the first TdP episode [no later than 24 h (median
6 h, range 1–22 h)], patients underwent a venous withdrawal
to determine serum electrolyte levels, including potassium,
sodium, calcium, and magnesium. Potassium and sodium were
determined by indirect potentiometry (COBAS-6000 platform);
values were expressed as mEq/L (reference values: potassium 3.5–
5.5; sodium 132–148). Calcium and magnesium were assayed
by a colorimetric method (COBAS-6000 platform); values
were expressed as mg/dl (reference values: calcium 8.0-11.0;
magnesium 1.5–2.5).
Only determinations obtained before the administration of
intravenous magnesium sulfate and/or replacement therapy with
potassium or calciumwere considered appropriate to be included
in the study. As a result, serum potassium, calcium ormagnesium
measurements were available in 45, 37, and 27 out of 48 patients,
respectively.
Other laboratory parameters included circulating levels of
anti-Ro/SSA antibodies (see Supplementary Methods for more
details) and C-reactive protein (CRP), as well as pH, bicarbonates
and serum glucose.
Statistical Analysis
To compare TdP patients subgroups, the following parametric
or non-parametric statistical analyses were respectively carried
out: the two-tail Student’s unpaired t-test, or the two-tail Mann-
Whitney test to evaluate differences in quantitative variables;
the Pearson or Spearman rank correlation-test to verify possible
statistical association between quantitative variables; the two-
sided Fisher’s exact test to evaluate statistical correlation between
categorical variables. p < 0.05 were considered as significant.
All statistical analyses were performed using GraphPad-InStat,
version 3.06 for Windows 2000.
RESULTS
TdP Patients Characteristics
As detailed in Table 1, demographic, clinical and laboratory
characteristics of our cohort were fully consistent with those
expected in TdP patients based on established epidemiological
data. In fact, the large majority of subjects were females (31/48,
65%) and older than 65 years (median age:∼80 years). Moreover,
many recognized QTc-prolonging risk factors of acquired origin
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FIGURE 1 | Electrocardiographic findings of a patient with TdP and PPI-associated hypomagnesemia. ECG strip in sinus rhythm (A) and during TdP (B) from a
patient who was under current and extended treatment with oral lansoprazole (15mg/day), and had low magnesium levels (1.46mg/dl) and a QTc of 670ms. Red
vertical lines and arrow in lead II show QT interval.
were identifiable, particularly an underlying cardiac disease
(45/48, 83%, more frequently ventricular hypertrophy, dilated
cardiomyopathy/heart failure and atrio-ventricular blocks),
electrolyte imbalances (37/47, 79%) and QTc-prolonging
medications (34/48, 71%). Hypokalemia occurred in 62% of
patients (28/45), thereby representing the most common specific
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risk factor. Anti-Ro/SSA-52 kD antibodies were detected in 56%
of the tested cases (18/32), although a history of autoimmune
disease was present in two patients only (1 rheumatoid arthritis, 1
celiac disease). Themajority of TdP patients (38/48, 79%) showed
signs of systemic inflammation, as indicated by the increase in
CRP levels (>0.5 mg/dl; median value 2.66 mg/dl). A definite
inflammatory disease was present in 22/48 patients (46%), most
commonly an acute infection (n = 15, particularly sepsis and
pneumonia), but also chronic immune-mediated diseases (n =
5, including 3 chronic inflammatory arthritis), or acute aseptic
inflammatory processes (n = 2). Among drugs, amiodarone
was the most frequently administered (14/48, 29%). Notably, in
almost all cases more than one known QTc-prolonging factor
was simultaneously identifiable; on average ∼5. In addition, a
significant proportion of patients (25/48, 52%) experienced an
adverse short-term arrhythmic outcome, i.e., VF/cardiac arrest
(CA), and/or underwent electric shock (TdP rapidly degenerated
to VF/CA; out-of-hospital VF/CA followed with DC-shock, only
later revealing a manifestation of TdP episodes; sustained TdP
not responsive to medical therapy).
Proton-Pump Inhibitors Usage in TdP
Patients
In our cohort, a significant percentage of patients were
under active treatment with PPI when TdP occurred (28/48,
58%). Many subjects (16/25, 64%) were taking a PPI for an
extended period of time, i.e., >2 weeks. The most frequently
administered PPI was pantoprazole, followed by lansoprazole,
together accounting for ∼85% of the cases (24/28). Remaining
patients (n = 4), were administered with omeprazole (n = 3), or
esomeprazole (n = 1). In three patients under extended home
PPI therapy, the molecule was changed during hospitalization,
before TdP development (from oral lansoprazole or pantoprazole
to intravenous pantoprazole in two cases; from oral omeprazole
to oral pantoprazole in the other one). The commonest route
of administration was the oral one, but in 6/28 cases (21%)
where the PPI was being given intravenously at the time of TdP
occurrence (Table 2). Notably, none of the intravenously-treated
patients showed hypomagnesemia.
Serum Electrolytes Levels and Other TdP
Risk Factors in Patients Taking or Not
Taking Proton-Pump Inhibitors
Consistently with the findings obtained in the whole TdP
population, a high prevalence of electrolyte imbalances
(collectively ∼80%) was found in both patients taking (PPI+)
or not taking PPI (PPI−). However, while the prevalence of
hypokaliemia and hypocalcemia as well as serum potassium,
calcium (and sodium) levels in the two groups were overalapping,
circulating magnesium levels were significantly lower in PPI+
than in PPI− subjects (1.60 ± 0.21 vs. 1.84 ± 0.33 mg/dl, 1 =
−0.24 mg/dl; p = 0.03) (Figures 2, 3). Hypomagnesemia (<1.5
mg/dl) occurred 5-times more frequently in the PPI+ vs. PPI-
group (6/14, 43% vs. 1/13, 8%), although this difference did
not reach statistical significance (p = 0.07) (Table 3). Notably,
hypomagnesemia was found almost exclusively (6 out of 7 cases,
TABLE 2 | Proton-pump inhibitors use in patients with Torsades de Pointes.
Patients under active treatment with PPIs, n 28/48(58%)
Specific PPI used, n
Pantoprazole 18/28(64%)
Lansoprazole 6/28(21%)
Omeprazole 3/28(11%)
Esomeprazole 1/28(4%)
Treatment duration*
Extended therapy (>2 weeks), n 16/25(64%)
Not extended therapy (<2 weeks), n 9/25(36%)
Daily dose, mg†
Pantoprazole 33.3 ± 9.7
Lansoprazole 27.5 ± 6.1
Omeprazole 26.7 ± 11.5
Esomeprazole 20
Route of administration, n†
Oral 22/28(79%)
Intravenous 6/28(21%)
Except where indicated otherwise, values are expressed as mean ± standard deviation.
*Data missing in 3 out of 28 patients.
†
At the moment of TdP occurrence.
85%) in patients receiving PPI therapy; all cases of PPI-associated
hypomagnesemia (n = 6) were observed in patients under
extended PPI therapy (>2 weeks), involving all the 4 different
PPIs used in the cohort (pantoprazole, n= 3; lansoprazole, n= 1;
omeprazole, n= 1; esomeprazole, n= 1). Diuretics usage, which
was not different in the PPI+ vs. PPI− group (Table 3), was
not per se associated with significant magnesium changes in our
cohort. In fact, by comparing patients taking (n = 16) and not
taking diuretics (n = 11), neither serum magnesium levels (1.67
± 0.31 vs. 1.78 ± 0.26 mg/dl; p = 0.32, two-tail unpaired t-test)
nor the prevalence of hypomagnesemia (6/16, 37% vs. 1/11, 9%; p
= 0.18, two-sided Fisher’s exact test) were significantly different.
Although these findings suggest that diuretics alone, differently
to PPIs alone, were not sufficient to cause magnesium depletion,
nevertheless diuretics may exacerbate PPI-associated magnesium
reduction when administered in association. Indeed, in patients
concomitantly receiving PPIs and diuretics (n = 9, vs. others n
= 18) serummagnesium levels further decreased slightly (1.55±
0.21 vs. 1.80 ± 0.30 mg/dl, 1 = −0,25 mg/dl; p = 0.02, two-tail
Mann-Whitney test), and the prevalence of hypomagnesemia
increased, reaching statistical significance (5/9, 56% vs. 2/18,
11%; p = 0.02, two-sided Fisher’s exact test). Despite a specific
investigation, no any significant impact of other common
causes of hypomagnesemia was found in our cohort of patients
(see Supplementary Results for more details). Moreover, no
significant correlation was present between magnesium levels
and other continuous variables, particularly calcium (r = 0.33,
p = 0.10; Pearson correlation-test) potassium (r = 0.10, p =
0.57; Pearson correlation-test), sodium (r = 0.11, p = 0.58;
Spearman rank correlation-test) or CRP levels (r = −0.14, p
= 0.46; Spearman rank correlation-test), or QTc duration (r =
−0.19, p= 0.32; Pearson correlation-test).
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FIGURE 2 | Serum magnesium levels in TdP patients taking or not taking PPIs.
Patients taking PPIs (PPI+), n = 14; patients not taking PPIs (PPI−), n = 13.
Two-tail Student’s unpaired t-test, *p < 0.05. Horizontal dotted line indicates
the lower limit of reference values for serum magnesium levels, i.e., 1.5 mg/dl.
As regards the other QTc-prolonging risk factors of acquired
origin, individually considered, no significant differences in
terms of concomitant diseases, both cardiac and extra.-cardiac,
QTc prolonging medications use, anti-Ro/SSA positivity or
presence of systemic inflammation were observed by comparing
PPI+ vs. PPI− patients (Table 3). Nevertheless, when all these
factors were considered together, also including electrolyte
imbalances, the mean QTc-prolonging risk factor number per
patient was significantly higher in the PPI+ than the PPI- group
(5.8 ± 1.6 vs. 4.9 ± 1.4, 1: 0.9; p = 0.04). Notably, statistical
significance of this difference was lost if hypomagnesemia, i.e.,
the only individual TdP risk factor discriminating the two
groups, was selectively excluded by the total count (5.6 ± 1.5
vs. 4.9 ± 1.4, 1: 0.7; p = 0.07; Table 3). It is important to
underline that for a number of patients, some data on QT-
prolonging risk factors were missing, particularly serum levels of
potassium (available in 26/28 of PPI+ 19/20 of PPI− patients,
respectively), calcium (27/28 of PPI+ and 18/20 of PPI− patients,
respectively), magnesium (14/28 of PPI+ and 13/20 of PPI−
patients, respectively), and anti-Ro/SSA positivity (18/28 of PPI+
and 14/20 of PPI− patients, respectively). Nevertheless, when we
restricted the analysis to patients with full data only, i.e., 8 PPI+
and 10 PPI−, differences (1) in mean QTc-prolonging risk factor
number per patient remained completely unchanged, both when
all risk factors were considered (6.1 ± 1.7 vs. 5.2 ± 1.3, 1: 0.9)
and when hypomagnesemia was excluded (5.8 ± 1.4 vs. 5.1 ±
1.3, 1: 0.7), thus indicating that the results were not influenced
by missing data.
Conversely, PPI treatment did not seem to affect the short-
term outcome in our cohort of patients. In fact, the percentage
of subjects experiencing VF/CA, and/or that underwent electric
shock was not significantly different by comparing PPI+ vs.
PPI− patients (15/28, 54% vs. 10/20, 50%) (Table 3).
Finally, in order to specifically address the question of whether
magnesium levels are different between PPI+ patients who
developed TdP vs. PPI+ patients who did not, 21 hospitalized
patients matched for age, gender and concomitant diseases
(Supplementary Table 1), but without QTc prolongation or
history of TdP were prospectively enrolled as a control group
(C). Similarly to that observed in TdP subjects, more than a
half of control patients were under current treatment with PPIs
(12/21, 57%), in most cases for an extended period of time
(10/12, 83%) (Supplementary Table 2). Among these patients,
hypomagnesemia was found in 2 patients (2/21, 9%), one treated
and one untreated with PPIs. As shown in Figure 4A, circulating
magnesium levels were significantly lower in TdP vs. controls
(1.72± 0.30 vs. 1.91± 0.40 mg/dl; p= 0.0094). Such a difference
significantly increased when the comparison was restricted to
PPI-treated patients from the two groups (TdP/PPI+: 1.60± 0.21
vs. C/PPI+: 1.93 ± 0.48 mg/dl; p = 0.0007; Figure 4B), while
serummagnesium levels were not different in PPI-untreated TdP
vs. control patients (TdP/PPI−: 1.84 ± 0.33 vs. C/PPI−: 1.88 ±
0.30 mg/dl; p= 0.78, two-tail Student’s unpaired t-test).
As a confirmation of the results on subgroups, we also
evaluated the interaction between magnesemia and PPI
treatment (PPI+/PPI−), by combining (multiplying) the two
variables in the whole population (TdP vs. C). We found that
sample differences between TdP and C in such interaction-
corrected levels of magnesium were not longer statistically
significant (p= 0.09, two-tail Mann-Whitney test).
DISCUSSION
The key findings of the present study are the following: a large
proportion of patients (>50%) who developed TdP were under
current treatment with a PPI; TdP patients taking PPIs had
significantly lower serum magnesium levels with respect to TdP
patients not taking PPIs; hypomagnesemia frequently occurred
in patients receiving PPIs (∼40%, 6/14), in all cases after an
extended period of time (>2 weeks) of administration; in subjects
taking PPIs the mean QTc-prolonging risk factor number per
patient was significantly higher than it was in those not taking
PPIs, a difference which was mainly driven by lower magnesium
levels.
Magnesium, representing the most abundant intracellular
divalent cation, plays a key role in regulating potassium and
calcium channels in the heart (Gupta et al., 2007). Experimental
studies demonstrated that cytosolic magnesium promotes
repolarization of myocardial cells via modulating effects on
several potassium currents, including the rapid component of the
delayed rectifier potassium current (IKr) and transient outward
current (Ito) (Kelepouris et al., 1993; El-Sherif and Turitto, 2011).
Moreover, magnesiummarkedly inhibits the L(long-lasting)-type
calcium current (ICaL), possibly as a result of a direct block of
the L-type-calcium channel pore by external magnesium or via
modification of the activity of protein kinases or phosphoprotein
phosphatases (Zhao et al., 2015). ICaL determines the plateau
phase thereby critically contributing to action potential duration
(APD) (Viskin, 1999; El-Sherif and Turitto, 2003). Moreover,
ICaL is the main depolarizing current that generates early
after depolarizations (EADs), in turn representing the primary
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FIGURE 3 | Serum levels of calcium, potassium and sodium in TdP patients taking or not taking PPIs. (A) Serum calcium levels. Patients taking PPIs (PPI+), n = 20;
patients not taking PPIs (PPI−), n = 17. Two-tail Student’s unpaired t-test (p > 0.05). Horizontal dotted line indicates the lower limit of reference values for calcium
levels, i.e., 8.0 mg/dl. (B) Serum potassium levels. PPI+, n = 27; PPI−, n = 18. Two-tail Student’s unpaired t-test (p > 0.05). Horizontal dotted line indicates the lower
limit of reference values for potassium levels, i.e., 3.5 mEq/L. (C) Serum sodium levels. PPI+, n = 28; PPI−, n = 20. Two-tail Student’s unpaired t-test (p > 0.05).
Horizontal dotted line indicates the lower limit of reference values for sodium levels, i.e., 132 mEq/L.
electrophysiological mechanism underlying TdP development
(Viskin, 1999; El-Sherif and Turitto, 2003). This supports the
fact that hypomagnesemia is a recognized risk factor for QTc
prolongation and TdP (Viskin, 1999; El-Sherif and Turitto, 2003,
2011), as well as the clinical evidence that magnesium sulfate is
very effective for the treatment of TdP thus being considered the
standard of care for this arrhythmia (Drew et al., 2010).
PPI-induced hypomagnesemia, for the first time described
in 2006, has been increasingly recognized in the last years
as a potentially life-threatening adverse event whose actual
incidence is probably largely underestimated (Famularo et al.,
2013). Two recent systematic reviews and meta-analysis, each
one including nine studies and over 100,000 patients, consistently
found that PPI users have a ∼40–80% higher risk of developing
hypomagnesemia when compared to non-users (Park et al., 2014;
Cheungpasitporn et al., 2015).
PPI-associated hypomagnesemia occurs after extended
treatments (>2 weeks, but in most cases > 1 year), is
not clearly dose-related, and was reported with different
PPIs, thus suggesting a class effect. Until PPI interruption,
hypomagnesemia is refractory to oral or parenteral magnesium
replacement irrespective of high-dose supplementation; when
the PPI is stopped, serum magnesium levels returned to
normal in less than 2 weeks (2011; Famularo et al., 2013).
However, hypomagnesemia may recur after re-challenge with
the same or a different PPI. In these patients, when prolonged
antiacid treatment is needed, prescription of a H2 histamine
receptor-blocker (H2-blocker) may be an appropriate therapeutic
alternative (Famularo et al., 2013). In fact, although mechanisms
of PPI-induced hypomagnesemia are not clear, hypochlorhydria
does not seem to be involved. Pathogenesis possibly includes
both gastrointestinal and renal losses, via dysfunction of the
Transient Receptor Potential Melastatin 6/7 (TRPM6/7) located
in the intestine as well as in the distal convoluted tubule
(Famularo et al., 2013). Accordingly, recent data suggest that
carriers of TRPM6 polymorphisms are at increased risk (Hess
et al., 2017).
To date only three reports of patients who developed TdP
while they were taking a PPI (i.e., omeprazole, pantoprazole, or
lansoprazole, respectively) (Asajima et al., 2012; Bibawy et al.,
2013; Hansen and Bruserud, 2016) have been described in the
literature, in two cases associated with hypomagnesemia (Bibawy
et al., 2013; Hansen and Bruserud, 2016). The results of the
present study suggest that the phenomenon is significantly more
common than reported, being probably underestimated because
in the clinical practice PPIs do not currently receive the due
attention as a factor potentially contributing to QTc prolongation
and TdP. Consistently with literature data (Famularo et al.,
2013), PPI-associated hypomagnesemia seems to be a class
effect which requires extended drug administration to occur.
In fact, although in our TdP patients most subjects used
pantoprazole, hypomagnesemia was found to be associated
with all 4 PPIs included in the AZCERT list (AZCERT, 2016)
(i.e., pantoprazole, omeprazole, esomeprazole, lansoprazole),
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TABLE 3 | Demographic, clinical and laboratory characteristics in proton pump
inhibitor users (PPI+) vs. non-proton pump inhibitor users (PPI−).
PPI+ PPI− p
Patients, n 28 20
Age, median years (interquartile range) 80.5(73–85) 81.5(75–87.5)0.40
Females, n 18/28(64%) 15/20(75%) 0.53
Mean QTc, ms 591.9 ± 88.8601.5 ± 70.10.69
FV/CA/EcS 15/28(54%) 10/20(50%) 1
Electrolyte imbalances, n 22/28(79%) 15/19(79%) 1
Hypokaliemia 17/27(63%) 11/18(61%) 1
Hypocalcemia 12/20(60%) 10/17(59%) 1
Hypomagnesemia 6/14(43%) 1/13(8%) 0.07
Potassium, mEq/L (r.v.3.5–5.5) 3.25 ± 0.61 3.41 ± 0.74 0.47
Calcium, mg/dl (r.v.8.0–11.0) 7.71 ± 0.67 7.85 ± 0.65 0.44
Magnesium, mg/dl (r.v.1.5–2.5) 1.60 ± 0.21 1.84 ± 0.33 0.03
Sodium, mEq/L (r.v.132–148) 139.1 ± 10.0 136.1 ± 2.9 0.23
Diuretics use, n 19/28(68%) 10/20(50%) 0.24
Furosemide median daily dose, mg (range) 25(10–100) 72.5(20–500)0.58
Glucose, mg/dl 171.2 ± 78.8172.8 ± 80.40.96
pH 7.46 ± 0.11 7.50 ± 0.12 0.53
Bicarbonates, mmol/L 25.4 ± 1.8 25.3 ± 2.2 0.97
Concomitant diseases*, n 26/28(93%) 19/20(95%) 1
Cardiac diseases 23/28(82%) 17/20(85%) 1
Extra-cardiac diseases 14/28(50%) 6/20(30%) 0.23
QTc prolonging-medications, n 21/28(75%) 13/20(65%) 0.52
Amiodarone 8/28(29%) 6/20(30%) 1
Mean medication number per patient 1.3 ± 1.1 1.0 ± 0.9 0.17
Anti-Ro/SSA positivity, n 8/18(44%) 10/14(71%) 0.16
Systemic inflammation, n 23/28(82%) 13/20(80%) 1
Mean QTc-prolonging risk factor number per patient
Per patient† 5.8 ± 1.6 4.9 ± 1. 0.04
Mean QTc-prolonging risk factor number
Per patient† excluding hypomagnesemia 5.6 ± 1.5 4.9 ± 1.4 0.07
Wherever not specified, data are expressed as mean±standard deviation. Appropriate
serum potassium, calcium or magnesium measurements available in 45, 37, and 27 out
of 48 patients, respectively; anti-Ro/SSA antibodies tested in 32 out of 48 patients.
VF, ventricular fibrillation; CA, cardiac arrest; EcS, electric shock.
*Diseases recognized to be a risk factor for QTc prolongation (Viskin, 1999; El-Sherif and
Turitto, 2003; Drew et al., 2010).
†
Including electrolyte imbalances, diseases, QTc-prolonging medications, anti-Ro/SSA
positivity, and systemic inflammation (Viskin, 1999; El-Sherif and Turitto, 2003; Drew et al.,
2010; Yue et al., 2015; Lazzerini et al., 2016, 2017b).
Differences were evaluated by the two-tailed unpaired t-test, or the two-tailed Mann-
Whitney test. Difference in categorical variables were evaluated by the two-sided Fisher’s
exact test.
Statistically significant p values are reported in bold.
in all cases administered for an extended period of time
(>2 weeks). Our data seem also to confirm that the risk
of PPI-induced hypomagnesemia further increases when PPIs
are co-administered with diuretics, probably as a result of
an enhancement of the renal loss of magnesium. Conversely,
although in PPI users hypomagnesemia has been reported
to be often accompanied by hypocalcemia and hypokalaemia
(Famularo et al., 2013), the prevalence of these electrolyte
imbalances as well as serum calcium, potassium and sodium
FIGURE 4 | Comparison of serum magnesium levels in TdP patients and
controls. (A) Serum magnesium levels in all TdP patients (n = 27) vs. controls
(C, n = 21), regardless of PPI therapy. Two-tail Mann-Whitney test, **p < 0.01.
(B) Serum magnesium levels in TdP patients under PPI therapy (TdP/PPI+) (n
= 14) vs. controls under PPI therapy (C/PPI+, n = 12). Two-tail Student’s
unpaired t-test, ***p < 0.001. Horizontal dotted line indicates the lower limit of
reference values for magnesium levels, i.e., 1.5 mg/dl.
levels were similar in PPI+ vs. PPI−TdP patients, thus indicating
a rather selective effect of this class of drugs onmagnesium levels.
Another important suggestion arising from the present study
is that PPI-associated changes in magnesium levels have a
relevant clinical impact by increasing the risk of developing
TdP in these patients. In fact, PPI users showed a significantly
higher mean total number of QTc-prolonging risk factors per
patient when compared to non-users. Nevertheless, despite a
comprehensive evaluation also taking into account recently
recognized “non-classical” QT-prolonging factors, such as anti-
Ro/SSA antibodies (Yue et al., 2015; Lazzerini et al., 2016, 2017d)
and systemic inflammatory activation (Lazzerini et al., 2015,
2017a,b), serum magnesium levels represented the only specific
TdP risk factor which was significantly different between the
two groups. Accordingly, when hypomagnesemia was excluded
from the total risk factor count, this difference was no longer
statistically significant.
Notably, we also found that magnesium levels in TdP/PPI+
patients were significantly lower when compared to C/PPI+
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matched for age, gender and concomitant diseases. It suggests
that TdP may act as a “clustering factor” for those patients,
among the general population, who are more susceptible to
the magnesium-lowering effect of PPIs, possibly as a result of
a genetic predisposition (Hess et al., 2017). This view, further
supporting the role of PPI-induced hypomagnesemia as a risk
factor for TdP, warrants specific investigation.
Although our data point to the conclusion that PPIs
can increase the risk of TdP by inducing hypomagnesemia,
the involvement of additional, possibly molecule-related
mechanisms could not be ruled out. In particular, this may be
the case of lansoprazole which has been recently associated to
an increased risk of QTc prolongation and TdP when used in
combination with ceftriaxone, via direct blocking effects of the
drug association on the hERG potassium channel (Lorberbaum
et al., 2016; Lazzerini et al., 2017c). Indeed, 2 patients in our
cohort were under current treatment with lansoprazole +
ceftriaxone when TdP occurred, in 1 case in the absence of
hypomagnesemia. Notably, it has been demonstrated that
also lansoprazole alone significantly inhibits hERG potassium
channel and related current IKr (−14%), although to a lesser
extent when compared to the drug combination (−58%)
(Lorberbaum et al., 2016). This may help explain why serum
magnesium level was normal in one out of three case reports
of PPI-associated TdP, in which lansoprazole administration
precipitated arrhythmia development in a patients under
long-term treatment with a drug known to directly prolong
QTc (disopyramide) (Asajima et al., 2012). Thus, it cannot be
ruled out that also in our patients, particularly those without
hypomagnesemia, lansoprazole (and possibly also the other
PPIs involved, since to date no specific patch-clamp studies are
available) could have contributed to promote TdP occurrence
also via a direct electrophysiological interference.
Our data suggest a number of important recommendations
to translate in the clinical practice. In particular, patients may
experience TdP in the presence of hypomagnesemia while
they were under active treatment with a PPI. Such patients
may be required to stop PPI treatment as it could have
significantly contributed to development and maintenance of
the electrolyte imbalance. Since it is expected that PPI-induced
hypomagnesemia is refractory to magnesium oral or parenteral
supplementation despite high doses (Famularo et al., 2013), drug
discontinuation is a key action to normalize serum magnesium
levels and thereby reduce the associated risk of TdP recurrence.
This measure may be of particular importance in patients
concomitantly requiring diuretic therapy, given the role of this
class of drugs in exacerbating magnesium depletion. Moreover,
based on the evidence that PPI-induced hypomagnesemia may
rapidly recur after re-challenge with the same or a different
PPI (median time ∼2 weeks; Famularo et al., 2013), the
alternative use of a H2-blocker may be appropriate in the
case the patient needs prolonged antiacid treatment. Finally,
since some data suggest that PPIs may also directly contribute
to QTc prolongation via electrophysiological effects on the
cardiomyocyte, it cannot be excluded that PPI discontinuation
could be a useful therapeutic measure even in TdP patients
without evidence of hypomagnesemia, particularly when the PPI
involved is lansporazole and other known QT-prolonging drugs
are concomitantly administered.
In conclusion, the present study demonstrates that PPI-
induced hypomagnesemia is a more than expected common
finding in unselected patients with TdP, significantly contributing
to increase the cumulative risk of developing this life-threatening
arrhythmia. Our real-life data provide important clinical
evidence in support to AZCERT recommendations which
cautiously already had warned about the potential role of
PPI-induced hypomagnesemia in promoting TdP, despite
only few cases were reported. Nevertheless, considering
the relative small sample size as well as the main focus on
magnesium levels, we did not perform any multivariate
analysis on our population. Since this may represent a
limitation of the study, larger sample studies are warranted
to confirm our results. They should include non-TdP
patients and/or younger populations, and could clarify
whether PPIs significantly influence the QTc also regardless
of hypomagnesemia.
In practice, more awareness is needed by the clinician when
a PPI is prescribed since the safety profile of this class of drugs
is probably not so neutral as commonly believed, specifically as
regards the risk of life-threatening arrhythmias and SCD.
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